---
schema_version: "secwatch.filing_event.v1"
accession: "0001815776-24-000058"
form_type: "8-K"
ticker: "LENZ"
cik: "0001815776"
company_name: "LENZ Therapeutics, Inc."
filed_at: "2024-08-14T23:59:59+00:00"
generated_at: "2026-05-31T09:23:56.034424+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# LENZ Therapeutics files NDA for LNZ100, reports Q2 net loss $10.3M, raises $30M via PIPE

## Summary
- NDA submitted to FDA for LNZ100 aceclidine eye drop for presbyopia, supported by positive Phase 3 CLARITY data.
- Q2 net loss $10.3M ($0.40/share) vs $14.7M ($7.53) in Q2 2023; R&D expenses fell to $6.9M from $12.6M.
- Cash, equivalents and securities $196.2M; pro forma after July $30M Ridgeback PIPE, $226.2M, expected to fund to post-launch positive cash flow.
- Phase 3 CLARITY: LNZ100 71% achieved 3-line near vision improvement at 3 hours, 40% at 10 hours, well-tolerated over 30,000 patient days.
- SG&A expenses rose to $7.4M from $2.3M on pre-commercial planning and public company costs.

## SEC filing metadata
- accession: 0001815776-24-000058
- form_type: 8-K
- ticker: LENZ
- cik: 0001815776
- company_name: LENZ Therapeutics, Inc.
- filed_at: 2024-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815776/000181577624000058/0001815776-24-000058-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815776/000181577624000058/lenz-20240814.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001815776-24-000058
- JSON: https://secwatch.observer/filing/0001815776-24-000058.json
- Plain text: https://secwatch.observer/filing/0001815776-24-000058.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.